WO2024231160A1 - Pharmaceutical or cosmetic composition for promoting hair growth - Google Patents

Abstract

Composition (C) comprising, for 100% by mass: from 20% by mass to 80% by mass of at least one sphingolipid (a1), from 10% by mass to 50% by mass of digalactosyldiacylglycerol (a2), and from 1% by mass to 30% by mass of at least one phospholipid (a3), for use in a therapeutic treatment method for promoting hair growth. Pharmaceutical composition (Cp) and food supplement (Ca) comprising said composition (C). Non-therapeutic use of said food supplement (Ca) and non-therapeutic method of implementation.

Description

PHARMACEUTICAL OR COSMETIC COMPOSITION FOR PROMOTING HAIR GROWTH The invention relates to the field of cosmetics and pharmacy. It concerns the treatment for promoting hair growth. The hair fiber consists of a visible shaft, a hair bulb, located under the surface of the scalp, and a dermal papilla located at the base of the bulb. The shaft is made up of three concentric layers: the medulla, the cortex and the cuticle. The medulla is the central part, while the cortex is the intermediate layer and constitutes the body of the hair. The cortex is composed of long chains of keratin which give the hair its elasticity, flexibility and resistance. The hair fiber is protected by the cuticle, formed by keratin scales sealed to each other by an intercellular cement rich in lipids and in particular ceramides. These lipid substances ensure the barrier function of the hair by giving it a certain impermeability. At its base, the shaft is surrounded by two sheaths: the outer epithelial sheath, which has a composition similar to the epidermis, and the inner epithelial sheath, rich in glycoproteins, constituting the nourishing base of the developing hair. The hair bulb is composed of keratinocytes whose active division is responsible for the formation of the hair shaft, as well as the inner and outer epithelial sheaths. The dermal papilla is a highly vascularized area and is the site of the cell multiplication necessary for hair growth. It is composed of fibroblasts and provides nutrition, irrigation, oxygenation and the elimination of cellular waste from the hair. Hair grows according to a growth cycle composed of three successive phases: the anagen phase (growth phase), the catagen phase (regression phase) and the telogen phase (resting phase). The anagen phase is a growth phase, lasting on average 2 to 4 years in men and up to 6 years in women. This phase is characterized by rapid proliferation and differentiation of keratinocytes to form the hair and epithelial sheaths. The intense metabolic activity at the bulb level leads to the formation of keratin, a protein essential to the composition of hair. Under normal conditions, approximately 85% of the hair is in the anagen phase. The catagen phase is a regression phase, lasting a short time of two to three weeks, constituting the transition phase between the growth phase and the resting phase. This phase is characterized by the involution of the hair follicle by a phenomenon of programmed death. Cell differentiation decreases until it stops. The volume of the bulb decreases, the latter rises towards the surface of the epidermis until it causes the physical link with the dermal papilla to break. This phase concerns approximately 1% of the hair. The telogen phase is a resting phase preceding hair loss, lasting an average of two to three months. This phase is characterized by an absence of cell proliferation. The dead hair remains attached to the hair follicle, and falls out when it is pushed back by a new hair, for which a new anagen phase begins. This phase concerns approximately 10 to 15% of the hair. Under the influence of different factors, this hair cycle can be altered. In particular, stress, fatigue, pollution, hormonal imbalance or drug treatment can cause abundant and non-localized hair loss, called telogen effluvium. In this case, the proportion of hair in the telogen phase increases, which can be greater than 20%. This is called telogen effluvium. This disorder generally lasts between two and four months and is accompanied by a weakening of the hair structure. The proportion of hair in the anagen and telogen phases can be assessed by performing a phototrichogram, a standardized method measuring the fundamental parameters related to hair growth. The phototrichogram is performed on a fixed area of the scalp with a diameter of 1.8 cm (frontotemporal region or vertex). The hair is shaved before an initial macrophotograph to count the total hair; a second macrophotograph taken 48 hours later then makes it possible to differentiate the anagen hair that has grown from the telogen hair that has not grown. As part of their research aimed at developing the use of natural compounds in therapy and cosmetics, the inventors have demonstrated that the use of a composition derived from wheat gluten extracts, administered orally, is capable of promoting hair growth (or growth), particularly in people suffering from alopecia or telogen effluvium. According to a first aspect, the invention thus relates to a composition (C) characterized in that it is a wheat gluten extract, comprising for 100% by mass: - from 20% by mass to 80% by mass of at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, - from 10% by mass to 50% by mass of digalactosyldiacylglycerol (a2), and - from 1% by mass to 30% by mass of at least one phospholipid (a3), and in that the sum of the mass contents of said at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, said digalactosyldiacylglycerol (a2) and said at least one phospholipid (a3), is equal to 100% by mass, for its oral use, in a therapeutic treatment method for promoting hair growth and more particularly for increasing the density and length of hair. For the purposes of the present invention, the term "sphingolipids" means complex lipids resulting from the amidation of a fatty acid on sphingosine. Sphingosine is an amido-diol having an ethylenic double bond; called 2-amino-octadec-4-ene-1,3-diol and of formula (I):

a sub-monoester group or and phosphoethanolamines, phosphatidylinositol, lysophosphatidylethanolamines, phosphatidic acids, phosphatidylcholine and lysophosphatidylcholines. According to a first particular aspect, the composition (C) as defined above comprises for 100% by mass from 20% by mass to 60% by mass, of at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine. According to a second particular aspect, the composition (C) as defined above comprises for 100% by mass from 19% by mass to 50% by mass, of digalactosyldiacylglycerol (a2). According to a third particular aspect, the composition (C) as defined above comprises for 100% by mass from 1% by mass to 10% by mass, of at least one phospholipid (a3). The invention more particularly relates to a composition (C) comprising for 100% by mass: - from 20% by mass to 60% by mass of at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, - from 19% by mass to 50% by mass of digalactosyldiacylglycerol (a2), and - from 1% by mass to 10% by mass of at least one phospholipid (a3) for its oral use, in a therapeutic treatment method for increasing the density and length of hair. According to another particular aspect of the invention, the composition (C) as defined above is in oily form or in powder form. Said composition (C) as defined above is prepared by methods known to those skilled in the art and more particularly that described in the international patent application published under number WO 99/65459, on pages 8 to 11. It is more particularly prepared according to a process comprising the following successive steps: - At least one step a) of providing wheat gluten flour, - At least one step b) of adding the wheat gluten flour to ethanol (97% minimum) with mechanical stirring for a period of at least two hours and at a temperature of 60°C, - At least one step c) of spinning followed by a sub-step of decanting the mixture obtained in step b) so as to recover a homogeneous liquid phase, - At least one step d) of vacuum distillation of the liquid obtained during step c), at a temperature less than or equal to 35°C to remove the ethanol so as to obtain a concentrated composition, - At least one step e) of adding the product obtained at the end of step d) to ethanol, with mechanical stirring and at a temperature of 4°C, so as to precipitate the medium and recover the liquid part, - At least one step f) of distilling the liquid obtained at the end of step e) to remove the ethanol and obtain an oily composition, - At least one step g) of adding composition (C) to acetone so as to obtain a precipitate, - At least one step h) of filtering the medium obtained at the end of step g) to recover a powdery solid, - drying the solid cake obtained at the end of step g) to obtain a composition in powder form. The present invention also relates to an edible pharmaceutical composition (Cp) comprising for 100% by mass: - more than 0% by mass to 30% by mass of said composition (C) as defined above and - from 70% by mass to less than 100% by mass of at least one pharmaceutically acceptable edible technological additive, for its oral use, in a therapeutic treatment method for increasing the density and length of hair. Preferably, said edible pharmaceutical composition (Cp) comprises for 100% by mass: - from 10% by mass to 30% by mass of a composition (C) comprising for 100% by mass: - from 20% by mass to 80% by mass, more particularly from 20% by mass to 60% by mass, of at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, - from 10% by mass to 50% by mass, more particularly from 19% by mass to 50% by mass, of digalactosyldiacylglycerol (a2), and - from 1% by mass to 30% by mass, more particularly from 1% by mass to 10% by mass, of at least one phospholipid (a3), the sum of the mass contents of said at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, said digalactosyldiacylglycerol (a2) and said at least one phospholipid (a3), being equal to 100% by mass, and said composition (C) being a wheat gluten extract, and - from 70% by mass to 90% by mass of at least one pharmaceutically acceptable edible technological additive, for its oral use, in a therapeutic treatment method for increasing the density and length of hair, more particularly in people suffering from alopecia or telogen effluvium. "Technological additive" means any chemical substance or chemical composition whose technical function is to enable and/or facilitate the mixing of the various constituents of said edible composition, to facilitate and/or optimize the physical properties of said edible composition, as well as to facilitate and/or optimize its flow, stability, and incorporation into a subsequent pharmaceutical and/or nutritional formulation, and which are capable of complying with the conditions required by the regulations in force for the placing on the market of a pharmaceutical formulation and/or a nutritional formulation. A pharmaceutically acceptable technological additive means a technological additive whose use meets the requirements of the pharmaceutical regulations in force in a country concerned. According to a particular aspect of the invention, said pharmaceutically acceptable edible technological additive is selected from a diluting agent, a flow agent, a binding agent or a disintegrating agent. As diluting agent, there are for example lactose, sucrose, saccharose, glucose, maltodextrin, mannitol, sorbitol, xylitol, isomalt, calcium hydrogen phosphate, microcrystalline cellulose, starches such as corn, wheat or potato starches, dicalcium phosphate, sodium, calcium or magnesium carbonates, monoglycerides and/or diglycerides of fatty acids comprising from 8 to 24 carbon atoms. Examples of flow agents include magnesium stearate, talc, sodium stearyl fumarate, hydrogenated vegetable oils, colloidal anhydrous silica, sodium benzoate or silicon dioxide. Examples of binding agents include starches in the form of starch, pregelatinized starches, hydroxypropylmethyl cellulose (HPMC), methylcellulose, sucrose syrups or gum acacia. Examples of disintegrating agents include starches, sodium starch glycolate, alginic acid, sodium alginate, croscarmellose sodium, crospovidone or polyvinylpyrrolidone. According to a particular aspect of the invention, said edible pharmaceutical composition (Cp) as defined above, further comprises at least one active ingredient chosen from bioactive lipids, water-soluble or water-dispersible trace element salts, water-soluble or fat-soluble vitamins, prebiotics, probiotics, proteins and/or milk protein concentrates, plant or animal enzymes, amino acids, peptides, sugars, flavor enhancers and flavoring agents. As bioactive lipids possibly present in said edible pharmaceutical composition (Cp) as defined above, there are for example phytosterols, such as those extracted from vegetable oils, and more particularly extracts of sea buckthorn oil, corn oil or soybean oil; phytosterol complexes isolated from vegetable oils, such as cholestatin composed of campesterol, stigmasterol and brassicasterol; phytostanols; carotenoids, which belong to the family of terpenoids extracted from algae, green plants, fungi, bacteria; polyunsaturated fatty acids of the omega-3 group, such as alpha-linoleic acid, eicosapentaenoic acid, docosahexaenoic acid; polyunsaturated fatty acids of the omega-6 group, such as linoleic acid, g-linoleic acid, eicosadienoic acid, dihomo-y-linoleic acid, arachidonic acid, docosadienoic acid, docosatetraenoic acid, docosapentaenoic acid. As salts of water-soluble or water-dispersible trace elements possibly present in said edible pharmaceutical composition (Cp) as defined above, there are for example ferrous carbonate, ferrous chloride tetrahydrate, ferric chloride hexahydrate, ferrous citrate hexahydrate, ferrous fumarate, ferrous lactate tetrahydrate, ferrous sulfate monohydrate, ferrous sulfate heptahydrate, ferrous chelate of amino acids hydrates, iron chelate of glycine; calcium iodate hexahydrate, anhydrous calcium iodate; sodium iodide, potassium iodide; cobalt acetate tetrahydrate, basic cobalt carbonate monohydrate, cobalt carbonate hexahydrate, cobalt sulfate heptahydrate, cobalt sulfate monohydrate, cobalt nitrate hexahydrate; cupric acetate monohydrate, basic copper carbonate monohydrate, cupric chloride dihydrate, copper methionate, cupric sulfate pentahydrate, cuprous chelate of amino acids hydrates, cuprous chelate of glycine hydrate, copper chelate of hydroxy analogue of methionine; manganous carbonate, manganous chloride tetrahydrate, manganese acid phosphate trihydrate, manganous sulfate tetrahydrate, manganous sulfate monohydrate, manganese chelate of amino acids hydrate, manganese chelate of glycine hydrate, manganese chelate of hydroxy analogue of methionine; ammonium molybdate, sodium molybdate, sodium selenite, sodium selenate; the organic form of selenium produced by saccharomyces cerevisiae, selenomethionine (inactivated selenium yeast), and seleno methionine produced by Saccharomyces cerevisiae (inactivated selenium yeast). As water-soluble or fat-soluble vitamins possibly present in said edible pharmaceutical composition (Cp) as defined above, there is for example vitamin A, more particularly in its form of retinol, retinyl acetate, retinyl palmitate or β-carotene; vitamin D2, more particularly in its form of dergocalciferol, or 25-hydroxy calciferol; vitamin D3, more particularly in its form of cholecalciferol; vitamin K, more particularly in its form of phylloquinone (phytomenadione) or menaquinone; vitamin B1, more particularly in its form of thiamine hydrochloride, thiamine mononitrate, thiamine chloride monophosphate, or thiamine chloride pyrophosphate, vitamin B2, more particularly in its form of riboflavin, sodium riboflavin 5'-phosphate, vitamin B6, more particularly in its form of pyridoxine hydrochloride, pyridoxine 5'-phosphate, or pyridoxal 5'-phosphate, vitamin B12, more particularly in its form of cyanocobalamin, hydroxocobalamin, 5'-deoxyadenosylcobalamin, or methylcobalamin, vitamin C, more particularly in its form of L-ascorbic acid, sodium L-ascorbate, calcium L-ascorbate, potassium L-ascorbate, calcium salts of palmityl-6-L-ascorbic acid, sodium ascorbyl monophosphate, pantothenic acid, more particularly in its form of calcium D-pantothenate, sodium D-pantothenate, Dexpanthenol, or Pantethine, vitamin PP, more particularly in its form of nicotinic acid, niacin, nicotinamide, or inositol hexanicotinate (inositol hexaniacinate), vitamin B9, more particularly in its form of folic acid, folates, more particularly in their form of pteroylmonoglutamic acid, calcium L-methylfolate, (6S)-5-methyltetrahydrofolic acid in the form of glucosamine salt, vitamin H2, B7 or BW, more particularly in its form of biotin, choline, more particularly in its form of choline chloride, choline dihydrogen citrate, choline bitartrate, inositol, carnitine, more particularly in its form of L-carnitine, L-carnitine-L-tartrate, taurine. As prebiotics possibly present in said edible pharmaceutical composition (Cp) as defined above, there are for example inulin, trans-galacto-oligosaccharides, fructans and manno-oligosaccharides. As probiotics possibly present in said edible pharmaceutical composition (Cp) as defined above, there are different strains of Saccharomyces cerevisiae, Bacillus cereus var. toyoi, Bacillus subtilis alone or in combination with Bacillus licheniformis, or strains of Enteroccocus faecium. These strains of microorganisms are generally associated with a solid support, for example calcium carbonate, dextrose or sorbitol. As proteins and/or protein concentrates possibly present in said edible pharmaceutical composition (Cp) as defined above, there are for example milk proteins derived from milk, such as colostrum in the form of freeze-dried or atomized powder or whey in the form of powder, purified fractions or enriched with IgG, lactoferrin, lactoperoxidase. As plant or animal enzymes possibly present in the edible pharmaceutical composition (Cp) as defined above, there are for example promutase, superoxide dismutase (SOD), 3-phytase, 6-phytase, endo-1,4-betaglucanases, endo-1,4-betaxylanases, or other enzymes improving or promoting digestion. As peptides possibly present in said edible pharmaceutical composition (Cp) as defined above, there are for example avocado peptides, lupin, quinoa peptides, maca peptides, fermented or unfermented soybean peptides, rice peptides, peptides present in Acacia macrostachya seed extract, peptides present in passionflower seed extracts. As amino acids possibly present in said edible pharmaceutical composition (Cp) as defined above, there are for example alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, hydroxy-proline, pyrrolysine, selmeno-cysteine, serine, threonine, tryptophan, tyrosine, valine, sarcosine, ornithine. As sugars possibly present in said edible pharmaceutical composition (Cp) as defined above, there are for example water-soluble polysaccharides, sugars of lower molecular weight, such as oligosaccharides, mono- or disaccharides, such as for example glucose, lactose, dextrose. As flavor enhancers possibly present in the edible pharmaceutical composition (Cp) as defined above, there are for example glutamates, such as glutamic acid, monosodium glutamate, monopotassium glutamate, calcium diglutamate, ammonium glutamate, magnesium diglutamate; guanylates, such as for example guanylic acid (guanosine monophosphate), disodium guanylate, dipotassium guanylate, calcium guanylate, inosinates, such as for example inosinic acid, disodium inosinate, dipotassium inosinate, calcium inosinate, or intense sweeteners such as Stevia extracts, Rebiaudosides. Said edible pharmaceutical composition (Cp) may be in solid or liquid form. According to a particular aspect of the invention, said edible pharmaceutical composition (Cp) is in the form of a solid, and more particularly the form of a tablet, a capsule, a soft capsule, a powder, a dragée, a confectionery gum or a granule. When the edible pharmaceutical composition (Cp) as defined above is in the form of a tablet, it preferably comprises from 50 mg to 150 mg of said composition (C) as defined above, for a 500 mg tablet; when it is in the form of a soft capsule, it preferably comprises from 120 mg to 360 mg of said composition (C) for a 1200 mg soft capsule; when it is in the form of a gelatin capsule, it preferably comprises from 10 mg to 30 mg of composition (C) for a 100 mg gelatin capsule; when it is in the form of a powder, it preferably comprises from 200 mg to 600 mg of composition (C) for a powder of 2000 mg. When the edible pharmaceutical composition (Cp) is in the form of a powder, it is obtained by introducing its various constituents into a mixer equipped with at least one mechanical stirring system, such as for example flat or propeller-type stirring blades, and the mixer is optionally a turning mixer, and the mixer is optionally equipped with a lump-forming system. This mixing operation is generally carried out at room temperature, in particular between 15°C and 30°C. When the edible pharmaceutical composition (Cp) is in the form of a confectionery gum, it preferably comprises from 150 mg to 450 mg of composition (C) for a confectionery gum of 1.5 g. When the edible pharmaceutical composition (Cp) is in the form of a liquid, it preferably comprises from 100 mg to 300 mg of composition (C) for a 1 ^cm3 ampoule. The invention also relates to the use in oral administration of an effective amount of a composition (C) comprising for 100% by mass: - from 20% by mass to 80% by mass, more particularly from 20% by mass to 60% by mass, of at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, - from 10% by mass to 50% by mass, more particularly from 19% by mass to 50% by mass, of digalactosyldiacylglycerol (a2), and - from 1% by mass to 30% by mass, more particularly from 1% by mass to 10% by mass, of at least one phospholipid (a3), the sum of the mass contents of said at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, of said digalactosyldiacylglycerol (a2) and of said at least one phospholipid (a3), being equal to 100% by mass and said composition (C) being a wheat gluten extract, for increasing the density and length of the hair. The invention also relates to a cosmetic treatment method intended to increase the density and length of the hair, characterized in that an effective amount of a composition (C) comprising for 100% by mass is administered orally: - from 20% by mass to 80% by mass, more particularly from 20% by mass to 60% by mass, of at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, - from 10% by mass to 50% by mass, more particularly from 19% by mass to 50% by mass, of digalactosyldiacylglycerol (a2), and - from 1% by mass to 30% by mass, more particularly from 1% by mass to 10% by mass, of at least one phospholipid (a3), the sum of the mass contents of said at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, said digalactosyldiacylglycerol (a2) and said at least one phospholipid (a3), being equal to 100% by mass and said composition (C) being a wheat gluten extract. For the purposes of the present invention, "hair growth" or "hair growth" means the increase in hair length and/or hair regrowth characterized by an increase in the total density of the hair, the density and the proportion of hair in the anagen phase. For the purposes of the present invention, "effective amount" means a sufficient amount that allows the consumer of average attention to visually observe the reality of the aesthetic aspect invoked with regard to the growth of his or her own hair, in particular the increase in hair length and/or hair regrowth. The experimental study set out in the remainder of the present description shows that an amount of between 1 mg and 250 mg, more particularly between 10 mg and 150 mg, even more particularly between 15 mg and 100 mg, and even more particularly between 30 mg and 70 mg of said composition, ingested per day, can be considered an effective amount. The present invention also relates to a food supplement (Ca) comprising for 100% by mass: - More than 0% by mass to 30% by mass of said composition (C) as defined above and - from 70% by mass to less than 100% by mass of at least one nutritionally acceptable technological additive. Preferably, the food supplement (Ca) as defined above comprises for 100% by mass: - more than 0% by mass and less than 10% by mass of a composition (C) comprising for 100% by mass: - from 20% by mass to 80% by mass, more particularly from 20% by mass to 60% by mass, of at least one sphingolipid (a1) resulting of the amidation of a fatty acid on sphingosine, - from 10% by mass to 50% by mass, more particularly from 19% by mass to 50% by mass, of digalactosyldiacylglycerol (a2), and - from 1% by mass to 30% by mass, more particularly from 1% by mass to 10% by mass, of at least one phospholipid (a3), the sum of the mass contents of said at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, said digalactosyldiacylglycerol (a2) and said at least one phospholipid (a3), being equal to 100% by mass and said composition (C) being a wheat gluten extract, and - more than 90% by mass and less than 100% by mass of at least one nutritionally acceptable technological additive. A dietary supplement is an edible composition whose purpose is to supplement the normal diet and which constitutes a concentrated source of nutrients or other substances having a nutritional or physiological effect alone or in combination. A dietary supplement helps to avoid certain deficiencies or to meet specific needs in an individual's diet, particularly during physical exertion. This definition of "dietary supplement" is given in Article 2 of Decree No. 2006-352 of March 26, 2006 of the French Republic relating to food supplements and in Directive 2002/46/EC of the European Parliament and of the Council of June 10, 2002. A "nutritionally acceptable technological additive" means a technological additive as defined above, the use of which meets the requirements of the regulations relating to food supplements in force in a given country. According to a particular aspect of the invention, said nutritionally acceptable technological additive is chosen from a diluting agent, a flow agent, a binding agent or a disintegrating agent. As diluting agent, there are for example lactose, sucrose, saccharose, glucose, maltodextrin, mannitol, sorbitol, xylitol, isomalt, calcium hydrogen phosphate, microcrystalline cellulose, starches such as corn, wheat or potato starches, dicalcium phosphate, sodium, calcium or magnesium carbonates, monoglycerides and/or diglycerides of fatty acids comprising from 8 to 24 carbon atoms. Examples of flow agents include magnesium stearate, talc, sodium stearyl fumarate, hydrogenated vegetable oils, colloidal anhydrous silica, sodium benzoate or silicon dioxide. As binding agents, there are for example starches in the form of starch, pregelatinized starches, hydroxypropylmethyl cellulose (HPMC), methylcellulose, sucrose syrups or gum acacia. As disintegrating agents, there are for example starches, sodium starch glycolate, alginic acid, sodium alginate, croscarmellose sodium, crospovidone, or polyvinylpyrrolidone. According to a particular aspect of the invention, said food supplement (Ca) as defined above, further comprises at least one active ingredient chosen from bioactive lipids, water-soluble or water-dispersible trace element salts, water-soluble or fat-soluble vitamins, prebiotics, probiotics, proteins and/or milk protein concentrates, plant or animal enzymes, amino acids, peptides, sugars, flavor enhancers and flavoring agents. As bioactive lipids possibly present in said food supplement (Ca) as defined above, there are for example phytosterols, such as those extracted from vegetable oils, and more particularly extracts of sea buckthorn oil, corn oil, or soybean oil; phytosterol complexes isolated from vegetable oils, such as cholestatin composed of campesterol, stigmasterol and brassicasterol; phytostanols; carotenoids, which belong to the family of terpenoids extracted from algae, green plants, fungi, bacteria; polyunsaturated fatty acids of the omega-3 group, such as alpha-linoleic acid, eicosapentaenoic acid, docosahexaenoic acid; polyunsaturated fatty acids of the omega-6 group, such as linoleic acid, g-linoleic acid, eicosadienoic acid, dihomo-y-linoleic acid, arachidonic acid, docosadienoic acid, docosatetraenoic acid, docosapentaenoic acid. As salts of water-soluble or water-dispersible trace elements possibly present in said food supplement (Ca) as defined above, there are for example ferrous carbonate, ferrous chloride tetrahydrate, ferric chloride hexahydrate, ferrous citrate hexahydrate, ferrous fumarate, ferrous lactate tetrahydrate, ferrous sulfate monohydrate, ferrous sulfate heptahydrate, ferrous chelate of amino acids hydrates, iron chelate of glycine; calcium iodate hexahydrate, anhydrous calcium iodate; sodium iodide, potassium iodide; cobalt acetate tetrahydrate, basic cobalt carbonate monohydrate, cobalt carbonate hexahydrate, cobalt sulfate heptahydrate, cobalt sulfate monohydrate, cobalt nitrate hexahydrate; cupric acetate monohydrate, basic copper carbonate monohydrate, cupric chloride dihydrate, cupric methionate, cupric sulfate pentahydrate, cuprous chelate of amino acids hydrates, cuprous chelate of glycine hydrate, copper chelate of hydroxy analogue of methionine; manganous carbonate, manganous chloride tetrahydrate, manganese acid phosphate trihydrate, manganous sulfate tetrahydrate, manganese sulfate monohydrate, manganese chelate of amino acids hydrate, manganese chelate of glycine hydrate, manganese chelate of hydroxy analogue of methionine; ammonium molybdate, sodium molybdate, sodium selenite, sodium selenate; the organic form of selenium produced by saccharomyces cerevisiae, selenomethionine (inactivated selenium yeast), and selenomethionine produced by Saccharomyces cerevisiae (inactivated selenium yeast). As water-soluble or fat-soluble vitamins possibly present in said food supplement (Ca) as defined above, there is for example vitamin A, more particularly in its form of retinol, retinyl acetate, retinyl palmitate or β-carotene; vitamin D2, more particularly in its form of dergocalciferol, or 25-hydroxy calciferol; vitamin D3, more particularly in its form of cholecalciferol; vitamin K, more particularly in its form of phylloquinone (phytomenadione) or Menaquinone; vitamin B1, more particularly in its form of thiamine hydrochloride, thiamine mononitrate, thiamine chloride monophosphate, or thiamine chloride pyrophosphate, vitamin B2, more particularly in its form of riboflavin, sodium riboflavin 5'-phosphate, vitamin B6, more particularly in its form of pyridoxine hydrochloride, pyridoxine 5'-phosphate, or pyridoxal 5'-phosphate, vitamin B12, more particularly in its form of cyanocobalamin, hydroxocobalamin, 5'-deoxyadenosylcobalamin, or methylcobalamin, vitamin C, more particularly in its form of L-ascorbic acid, sodium L-ascorbate, calcium L-ascorbate, potassium L-ascorbate, calcium salts of palmityl-6- L-ascorbic acid, sodium ascorbyl monophosphate, pantothenic acid, more particularly in its form of calcium D-pantothenate, sodium D-pantothenate, Dexpanthenol, or Pantethine, vitamin PP, more particularly in its form of nicotinic acid, niacin, nicotinamide, or inositol hexanicotinate (inositol hexaniacinate), vitamin B9, more particularly in its form of folic acid, folates, more particularly in their form of pteroylmonoglutamic acid, calcium L-methylfolate, (6S)-5-methyltetrahydrofolic acid in the form of glucosamine salt, vitamin H2, B7 or BW, more particularly in its form of biotin, choline, more particularly in its form of choline chloride, choline dihydrogen citrate, choline bitartrate, inositol, carnitine, more particularly in its form of L-carnitine, L-carnitine-L-tartrate, taurine. As prebiotics possibly present in said food supplement (Ca) as defined above, there are for example inulin, trans-galacto-oligosaccharides, fructans and manno-oligosaccharides. As probiotics possibly present in said food supplement (Ca) as defined above, there are different strains of Saccharomyces cerevisiae, Bacillus cereus var toyoi, Bacillus subtilis alone or in combination with Bacillus licheniformis, or strains of Enteroccocus faecium. These strains of microorganisms are generally associated with a solid support, for example calcium carbonate, dextrose or sorbitol. As proteins and/or protein concentrates possibly present in said food supplement (Ca) as defined above, there are for example milk proteins from milk, such as colostrum in the form of freeze-dried or atomized powder or whey in the form of powder, purified fractions or enriched with IgG, lactoferrin, lactoperoxidase. As plant or animal enzymes possibly present in said food supplement (Ca) as defined above, there are for example promutase, superoxide dismutase (SOD), 3-phytase, 6-phytase, endo-1,4-betaglucanases, endo-1,4-betaxylanases, or other enzymes improving or promoting digestion. As peptides possibly present in said food supplement (Ca) as defined above, there are for example avocado peptides, lupin peptides, quinoa peptides, maca peptides, fermented or non-fermented soy peptides, rice peptides, peptides present in Acacia macrostachya seed extract, peptides present in passionflower seed extracts. As amino acids possibly present in said food supplement (Ca) as defined above, there are for example alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, hydroxy-proline, pyrrolysine, selmeno-cysteine, serine, threonine, tryptophan, tyrosine, valine, sarcosine, ornithine. As sugars possibly present in said food supplement (Ca) as defined above, there are for example water-soluble polysaccharides, sugars of weight lower molecular weight, such as oligosaccharides, mono- or disaccharides, such as glucose, lactose, dextrose. As flavor enhancers possibly present in said food supplement (Ca) as defined above, there are for example glutamates, such as glutamic acid, monosodium glutamate, monopotassium glutamate, calcium diglutamate, ammonium glutamate, magnesium diglutamate; guanylates, such as guanylic acid (guanosine monophosphate), disodium guanylate, dipotassium guanylate, calcium guanylate, inosinates, such as inosinic acid, disodium inosinate, dipotassium inosinate, calcium inosinate, or intense sweeteners such as Stevia extracts, Rebiaudosides. Said food supplement (Ca) can be in solid or liquid form. Said food supplement (Ca) may be in any form of food product known to those skilled in the art, such as a drink, and more particularly an aqueous drink, a solution, a fruit juice, a flavored drink, an energy drink, an alcoholic drink, a coffee-based drink, a chocolate-based drink, a tea-based drink, a dairy product, and more particularly milk, yogurt, a dairy dessert, drinkable yogurt, cheese, ice cream, a chocolate bar, a cereal product, and more particularly a cereal bar, a biscuit, breakfast cereals, flours, bakery products, a specialized nutrition product, more particularly an infant nutrition product, a nutrition product to prepare for physical exercise, a clinical nutrition product, a meal replacement, confectionery, more particularly chewing gum, sweets, caramels, sugared almonds, berlingots, marshmallows, lokoums, nougats, fruit pastes, liquorice. The food supplement (Ca) according to the invention may also be in any galenic form known to those skilled in the art, such as for example in the form of a tablet, a capsule, a soft capsule, a syrup, a powder, such as for example an immediate-release powder, a delayed-release powder or a powder for reconstituted drinks, a liquid, a stick, a gel. According to a particular aspect of the invention, said food supplement (Ca) as defined above, is in the form of a solid, and more particularly the form of a tablet, a capsule, a soft capsule, a powder, a dragée, a confectionery gum or a granule. When said food supplement (Ca) as defined above, is in the form of a tablet, it preferably comprises less than 50 mg of said composition (C) such that defined above, for a 500 mg tablet; when it is in the form of a soft capsule, it preferably comprises less than 120 mg of said composition (C) for a 1200 mg soft capsule; when it is in the form of a gelatin capsule, it preferably comprises less than 10 mg of said composition (C) as defined above for a 100 mg gelatin capsule; when it is in the form of a powder, it preferably comprises less than 200 mg of said composition (C) as defined above for a 2000 mg powder. When said food supplement (Ca) is in the form of a powder, it is obtained by introducing its various constituents into a mixer equipped with at least one mechanical stirring system, such as for example flat or propeller-type stirring blades, and the mixer is optionally a percolator mixer, and the mixer is optionally equipped with a lump-chopper system. This mixing operation is generally carried out at room temperature, in particular between 15°C and 30°C. When said food supplement (Ca) is in the form of a confectionery gum, it preferably comprises less than 150 mg of said composition (C) as defined above for a 1.5 g confectionery gum. When the food supplement (Ca) is in the form of a liquid, it preferably comprises less than 100 mg of said composition (C) as defined above for a 1 cm ³ ampoule. The present invention also relates to the cosmetic use in oral administration of the food supplement (Ca) as defined above, to increase the density and length of hair. Finally, the present invention relates to a cosmetic treatment method intended to increase the density and length of hair, characterized in that an effective amount of the food supplement (Ca) as defined above is administered orally. According to a particular aspect of the invention, said food supplement (Ca) as defined above is administered orally at a rate of at least 15 mg, in particular at least 30 mg, of said composition (C) per day for at least 4 weeks, in particular for at least 8 weeks, even more particularly for 12 weeks. The following examples illustrate the invention, without however limiting it. Comparative formulations A commercial wheat gluten extract is used in the form of a powdery composition (C) which comprises for 100% of its mass: 52.5% by mass of sphingolipids, 41.5% by mass of DigalactosylDiacylGlycerol and 6% by mass of phospholipids. Two formulations were prepared, respectively a dietary supplement (Ca) (comprising composition (C)) and a dietary supplement (C'a) (not comprising composition (C)), which comprise the ingredients as shown in Table 1: [Table 1] Amount per capsule Components Dietary supplement (Ca) Dietary supplement (C'a) Composition (C) 15 mg - Maltodextrin 230 mg 245 mg Dicalcium phosphate 100 mg 100 mg Magnesium carbonate 50 mg 50 mg Silica 30 mg 30 mg Magnesium stearate 10 mg 10 mg Total net weight 435 mg 435 mg Total weight 549 mg 549 mg (including capsule weight) 5 Procedure The technical effect of composition (C) was demonstrated in a pilot, randomized, double-blind, parallel-group clinical study. It tested the effect of daily consumption of 30 mg of (C) versus Placebo over a period of 84 days (12 weeks). 10 Caucasian women aged between 18 and 65 years, with telogen effluvium (proportion of hair in the telogen phase > 15%) and complaining of fine and brittle hair, as well as a sebum level greater than or equal to 140 µg/cm², were included in the study. They consumed for 84 days (from D0 to D84) or 2 capsules per day of the supplement food supplement (Ca) or 2 capsules per day of the food supplement (C'a). The measurements were carried out on day 0 (D0) and 56 (D56) and 84 days (D84). A.1- Hair length: Principle of the evaluation method Hair growth was evaluated by measuring the length of 5 hairs after 84 days of supplementation, following their shaving on D0. The improvement in hair growth was also highlighted by the study subjects, thanks to the use of a self-assessment form. Results The results obtained are presented in Table 2. [Table 2] Dietary supplement (C'a) Dietary supplement (Ca) (number of subjects = 32) (number of subjects = 33) Mean ± SEM Mean ± SEM (p vs placebo) D84 3.2 ± 0.1 3.6 ± 0.1 (p=0.0001) SEM: standard error of the measurement Observations - Comments By measuring hair growth at D84 after shaving at D0, a significant increase in hair length was observed between the dietary supplement (Ca) group (containing composition (C)) and the dietary supplement (C'a) group (3.6 ± 0.1 cm vs 3.2 ± 0.1 cm; p<0.001). In addition, after analyzing the responses from the qualitative form, a proportion of 91% of subjects in the dietary supplement group (Ca) reported that their “hair grew faster”, compared to 72% of subjects in the dietary supplement group (C'a). A.2- Hair regrowth: Principle of the evaluation method Hair regrowth was evaluated by performing a phototrichogram, allowing the density and proportion of hair in the anagen and telogen phases to be quantified. As a reminder, the phototrichogram is performed on a fixed area of the scalp with a diameter of 1.8 cm (frontotemporal region or vertex). The hair is shaved there, before coloring the area and taking a first macrophotograph allowing the total hair to be counted; A second macrophotograph taken 48 hours later then allows to differentiate the anagen hairs that have grown from the telogen hairs that have not grown. The total hair density is evaluated by the total number of hairs per cm². The anagen hair density is evaluated by the number of hairs in the anagen phase (having grown during the 48 hours between the 2 macrophotographs) per cm² and proportion (%) compared to the total hair density. Hair regrowth was also analyzed through a clinical evaluation carried out by a dermatologist as well as using a self-assessment form completed by the study subjects. A.2.1- Hair density in the anagen phase: Results The results obtained are presented in Table 3. [Table 3] Food supplement C'a Food supplement Ca (number of subjects = 32) (number of subjects = 33) Mean ± SEM Mean ± SEM % vs D0 % vs D0 (p vs D0) (p vs D0) (p vs placebo) D0 162.6 ± 4.9 - 165.5 ± 3.8 - 173.0 ± 4.2 +4.6% D56 162.8 ± 6.1 -0.13% (p=0.0005) (p=0.043) 170.8 ± 4.9 184.6 ± 4.1 +11.9% D84 +5.6% (p=0.004) (p=0.0001) (p=0.004) SEM: standard error of the measurement Observations - Comments A significant increase in hair density in the anagen phase was observed in the food supplement group (Ca) after 56 days of consumption: from 165.5 ± 3.8 hairs/cm² on D0 to 173.0 ± 4.2 hairs/cm² on D56 (p=0.0005) and 184.6 ± 4.1 hairs/cm² on D84 (p=0.0001), whereas a significant increase was only observed in the food supplement group (C'a) after 84 days of consumption: from 162.6 ± 4.9 hairs/cm² on D0 to 162.8 ± 6.1 hairs/cm² on D56 and 170.8 ± 4.9 hair/cm² at D84 (p=0.004). In addition, there was a significant difference between the food supplement group (Ca) and the food supplement group (C'a) at D56 (+4.6% vs -0.13%; p=0.043) as well as at D84 (+11.9% vs +5.6%; p=0.004). A.2.2- The proportion of hair in the anagen phase: Results The results obtained are presented in Table 4. [Table 4] Dietary supplement (C'a) Dietary supplement (Ca) (number of subjects = 32) (number of subjects = 33) Mean ± SEM Mean ± SEM % vs D0 % vs D0 (p vs D0) (p vs D0) (p vs placebo) D0 81.2 ± 0.5 - 80.9 ± 0.6 - 84.4 ± 0.6 +4.3% D56 82.3 ± 0.8 +1.3% (p=0.0001) (p=0.003) 83.2 ± 0.6 86.0 ± 0.6 +6.5% D84 +2.5% (p=0.002) (p=0.0001) (p=0.0001) SEM: standard error of the measurement Observations - Comments A significant increase in the proportion of hair in the anagen phase was observed in the food supplement group (Ca) after 56 days of consumption: from 80.9 ± 0.6% on D0 to 84.4 ± 0.6% on D56 (p=0.0001) and 86.0 ± 0.6% on D84 (p=0.0001), while a significant increase was observed in the food supplement group (C'a) only after 84 days of consumption: from 81.2 ± 0.5% on D0 to 82.3 ± 0.8% on D56 and 83.2 ± 0.6% on D84 (p=0.002). In addition, there is a significant difference between the food supplement group (Ca) and the food supplement group (C'a) at D56 (+4.3% vs +1.3%; p=0.003) and D84 (+6.5% vs +2.5%; p=0.0001). A.2.3- Total hair density: Results The results obtained are presented in Table 5. [Table 5] Dietary supplement (C'a) Dietary supplement (Ca) (number of subjects = 32) (number of subjects = 33) Mean ± SEM Mean ± SEM % vs D0 % vs D0 (p vs D0) (p vs D0) (p vs placebo) D0 200.5 ± 6.3 - 205.1 ± 5.1 - D56 197.7 ± 7.0 -1.5% 205.3 ± 5.1 +0.2% 214.9 ± 5.0 D84 205.4 ± 6.0 +2.9% +5.1% (p=0.0001) SEM: standard error of the measurement Observations - Comments A significant increase in total hair density was observed in the dietary supplement (Ca) group after 84 days of consumption: 205.1 ± 5.1 hairs/cm² at D0 to 214.9 ± 5.0 hairs/cm² at D84 (p=0.0001), whereas there was no significant change in the food supplement group (C'a): from 200.5 ± 6.3 hairs/cm² at D0 to 205.4 ± 6.0 hairs/cm² at D84. An increase in total hair density was also noted by clinical assessment (performed by a dermatologist) in 61% of subjects in the dietary supplement (Ca) group at D56 (vs. 47% of subjects in the dietary supplement (C'a) group), and in 64% of subjects in the dietary supplement (Ca) group at D84 (vs. 53% of subjects in the dietary supplement (C'a) group). This increase was also evidenced by the study subjects, with 85% of subjects in the dietary supplement (Ca) group reporting that their “scalp was more covered”, compared to 75% of subjects in the dietary supplement (C'a) group. A.3 Conclusions Through the clinical study, composition (C) demonstrated activity in promoting hair growth, through its effect on increasing hair length, and its effect on anagen density and total density. Examples of illustrative formulations [Table 6] Clinical Study Capsule Formula Component Amount per Capsule Composition (C) 15 mg Maltodextrin 230 mg Dicalcium Phosphate 100 mg Magnesium Carbonate 50 mg Silica 30 mg Magnesium Stearate 10 mg [Table 7] Capsule Formula Component Amount per Capsule Composition (C) 30 mg Maltodextrin 220 mg Beet Juice 70 mg Magnesium Stearate 15 mg 5

[Table 8] Softgel Capsule Formula Component Quantity per Capsule Composition (C) 70 mg Borage oil 400 mg Glyceryl monostearate 24.1 mg Vitamin C 14.6 mg Lecithin 14 mg Vitamin B3 2.9 mg Vitamin E 2.7 mg Selenium 2 mg Copper 0.4 mg Vitamin B2 0.2 mg Biotin 0.007 mg Bibliography 5 (1) Lin et al. Morphogenesis, Growth Cycle and Molecular Regulation. Frontiers in Cell and Developmental Biology 2022, 10:899095. (2) Patent application FR3069160A1: Cosmetic or pharmaceutical composition promoting hair growth comprising a lyophilisate of dedifferentiated sea fennel cells. 10 (3) Nikfar & Jaberidoost. Hair In Encyclopedia of Toxicology (Third Edition), Academic Press, 2014, 813-815. (4) Patent application EP2821052A1: Association of miliacin and polar lipids, in particular sphingolipids and/or phospholipids, for the care of hair and scalp. (5) Yin et al. Telogen Effluvium – a review of the science and current obstacles. Journal of Dermatological Science 2021, 101, 156-163. (6) Hoffmann. TrichoScan: A Novel Tool For The Analysis of Hair Growth In Vivo. Journal of Investigative Dermatology Symposium Proceedings 2003, 8, 109-115.

Claims

CLAIMS 1. Composition (C) characterized in that it is a wheat gluten extract, comprising for 100% by mass: - from 20% by mass to 80% by mass of at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, - from 10% by mass to 50% by mass of digalactosyldiacylglycerol (a2), and - from 1% by mass to 30% by mass of at least one phospholipid (a3), and in that the sum of the mass contents of said at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, of said digalactosyldiacylglycerol (a2) and of said at least one phospholipid (a3), is equal to 100% by mass, for its oral use, in a method of therapeutic treatment for increasing hair density and length. 2. Composition (C) according to claim 1, comprising for 100% by mass: - from 20% by mass to 60% by mass of at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, - from 19% by mass to 50% by mass of digalactosyldiacylglycerol (a2), and - from 1% by mass to 10% by mass of at least one phospholipid (a3). 3. Edible pharmaceutical composition (Cp) comprising for 100% by mass: - from 10% by mass to 30% by mass of a composition (C) comprising for 100% by mass: - from 20% by mass to 80% by mass, more particularly from 20% by mass to 60% by mass, of at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, - from 10% by mass to 50% by mass, more particularly from 19% by mass to 50% by mass, of digalactosyldiacylglycerol (a2), and - from 1% by mass to 30% by mass, more particularly from 1% by mass to 10% by mass, of at least one phospholipid (a3), the sum of the mass contents of said at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, said digalactosyldiacylglycerol (a2) and said at least one phospholipid (a3), being equal to 100% by mass, and said composition (C) being a wheat gluten extract, and - from 70% by mass to 90% by mass of at least one pharmaceutically acceptable edible technological additive, for its oral use, in a therapeutic treatment method for increasing the density and length of hair. 4. Edible pharmaceutical composition (Cp) according to claim 3, further comprising at least one active ingredient chosen from bioactive lipids, water-soluble or water-dispersible trace element salts, water-soluble or fat-soluble vitamins, prebiotics, probiotics, proteins and/or milk protein concentrates, plant or animal enzymes, amino acids, peptides, sugars, flavor enhancers and flavoring agents. 5. Use in oral administration of an effective amount of a composition (C) comprising for 100% by mass: from 20% by mass to 80% by mass, more particularly from 20% by mass to 60% by mass, of at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, - from 10% by mass to 50% by mass, more particularly from 19% by mass to 50% by mass, of digalactosyldiacylglycerol (a2), and - from 1% by mass to 30% by mass, more particularly from 1% by mass to 10% by mass, of at least one phospholipid (a3), the sum of the mass contents of said at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, of said digalactosyldiacylglycerol (a2) and said at least one phospholipid (a3), being equal to 100% by mass and said composition (C) being a wheat gluten extract, for increasing the density and length of the hair. 6. Cosmetic treatment method intended to increase the density and length of the hair, characterized in that an effective amount of a composition (C) comprising for 100% by mass is administered orally: - from 20% by mass to 80% by mass, more particularly from 20% by mass to 60% by mass, of at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, - from 10% by mass to 50% by mass, more particularly from 19% by mass to 50% by mass of digalactosyldiacylglycerol (a2), and - from 1% by mass to 30% by mass, more particularly from 1% by mass to 10% by mass, of at least one phospholipid (a3), the sum of the mass contents of said at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, of said digalactosyldiacylglycerol (a2) and of said at least one phospholipid (a3), being equal to 100% by mass and said composition (C) being a wheat gluten extract. 7. Food supplement (Ca) Food supplement (Ca) comprising for 100% by mass: - more than 0% by mass and less than 10% by mass of a composition (C) comprising for 100% by mass: - from 20% by mass to 80% by mass, more particularly from 20% by mass to 60% by mass, of at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, - from 10% by mass to 50% by mass, more particularly from 19% by mass to 50% by mass, of digalactosyldiacylglycerol (a2), and - from 1% by mass to 30% by mass, more particularly from 1% by mass to 10% by mass, of at least one phospholipid (a3), the sum of the mass contents of said at least one sphingolipid (a1) resulting from the amidation of a fatty acid on sphingosine, said digalactosyldiacylglycerol (a2) and said at least one phospholipid (a3), being equal to 100% by mass and said composition (C) being a wheat gluten extract, and - more than 90% by mass and less than 100% by mass of at least one nutritionally acceptable technological additive. 8. Food supplement (Ca) according to claim 7, further comprising at least one active ingredient chosen from bioactive lipids, water-soluble or water-dispersible trace element salts, water-soluble or fat-soluble vitamins, prebiotics, probiotics, proteins and/or milk protein concentrates, plant or animal enzymes, amino acids, peptides, sugars, flavor enhancers and flavoring agents. 9. Food supplement (Ca) according to any one of claims 7 or 8, characterized in that it is in the form of a tablet, a capsule, a soft capsule, a powder, a dragée, a confectionery gum or a granule. 10. Cosmetic use in oral administration of the food supplement (Ca) according to any one of claims 7 to 9, to increase the density and length of hair. 11. Cosmetic treatment method intended to increase the density and length of hair, characterized in that an effective amount of the food supplement (Ca) according to any one of claims 7 to 9 is administered orally.